Acquisition of Divested Products from the Watson/Actavis Merger (Details) (Watson/Actavis Divestiture Products [Member], USD $) In Thousands, unless otherwise specified	0 Months Ended
	Nov. 06, 2012	Nov. 06, 2012 product drug_application
Watson/Actavis Divestiture Products [Member]
Business Acquisition [Line Items]
Number of generic products with marketing rights acquired through merger (products)	5	5
Number of abbreviated new drug applications awaiting regulatory approval (drug applications)	8	8
Purchase price	$ 110,000
Supply agreement term (years)	3 years